Jump to content

Wikipedia talk:WikiProject Pharmacology

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
(Redirected from Wikipedia talk:Pharm)

WikiProject iconPharmacology Project‑class
WikiProject iconThis page is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
ProjectThis page does not require a rating on Wikipedia's content assessment scale.


Hello

[edit]

Howdy folks, I’ve been invited by

WhatamIdoing to contribute here and at the Medicine project. I’m a subject matter expert in these fields with >15 yrs experience across various fields of medicine, including product development, patient care, and basic science. I welcome you to reach out for support with existing articles or to contribute to new topics. See you around! Gobucks821 (talk) 14:57, 17 January 2024 (UTC)[reply]

@Gobucks821: A (rather belated!) welcome over here. There don't seem to be many of us watching WikiProject Pharmacology! Regardless, let's push on. It will be great to have you working on this project too! Klbrain (talk) 09:10, 7 May 2024 (UTC)[reply]

Leonurine

[edit]

The article leonurine was tagged with the {{More medical citations needed}} warning template in 2021. Since then, the article has accumulated much more content that appears to be supported only low-quality references and/or primary references that are inconsistent with Wikipedia:Identifying reliable sources (medicine). If someone with subject expertise could have a look, particularly at the "Pharmacology" section, that would be appreciated. Thank you. Marbletan (talk) 20:48, 6 February 2024 (UTC)[reply]

Tricaprin

[edit]

I noticed a gap in the coverage of this specific triglyceride with a lot of work being done in recent decades, tricaprin, and would like some eyes on it as I work on getting the article ready for mainspace. I'm new to working on chemical articles with pharmacological applications and want to make sure I'm not putting in primary research to support medical claims here or otherwise giving undue weight to certain applications: Draft:Tricaprin Reconrabbit 17:04, 12 April 2024 (UTC)[reply]

I've had a look at your draft; you are using primary sources, but you're using them as a statement of fact (that there are clinical trials for ...) rather than a claim of utility (that they are helpful for ...). So, my view is that what you've written is fine and helpful! Klbrain (talk) 09:07, 7 May 2024 (UTC)[reply]
I only felt comfortable using language stronger than just "has been studied" when citing the NCI Dictionary. Thanks for taking a look. Once the production info is filled in I will publish. Reconrabbit 12:15, 7 May 2024 (UTC)[reply]

Sunobinop improvements

[edit]

Greetings! I'm Valentine, an employee of Imbrium Therapeutics, the company developing sunobinop. Because of my conflict of interest, I posted suggestions to improve the sunobinop article at Talk:Sunobinop#Sunobinop article improvements and included the template for requesting an edit. I'm posting here since it's a more specialized topic and I thought this group might be interested. Thanks, ImbriumValentine (talk) 20:10, 6 May 2024 (UTC)[reply]

 Done Klbrain (talk) 09:00, 7 May 2024 (UTC)[reply]

Integrate definitive new findings

[edit]

Much of the staggering mortality rates and health care costs associated with drug-induced liver injury (DILI) is clearly linked to 11 drugs not well-known for their hepatotoxic risk, per the editorial accompanying https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2820267, which just came out.[1] Lets get this added to the 11 to 17 relevant articles, liver failure, etc.RememberOrwell (talk)

References

  1. ^ Torgersen, Jessie; Mezochow, Alyssa K.; Newcomb, Craig W.; Carbonari, Dena M.; Hennessy, Sean; Rentsch, Christopher T.; Park, Lesley S.; Tate, Janet P.; Bräu, Norbert; Bhattacharya, Debika; Lim, Joseph K.; Mezzacappa, Catherine; Njei, Basile; Roy, Jason A.; Taddei, Tamar H.; Justice, Amy C.; Lo Re, Vincent (24 June 2024). "Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data". JAMA Internal Medicine. doi:10.1001/jamainternmed.2024.1836. ISSN 2168-6106.
This is a cohort study, which is classified as primary. Per WP:MEDRS, secondary sources (review articles) are needed to support medical claims. Furthermore the accompanying editorial describes this cohort study as an "innovative methodologic approach". We need to wait for this study to be evaluated in reliable secondary sources before citing those secondary sources. Boghog (talk) 05:46, 26 June 2024 (UTC)[reply]
Thanks for the feedback and help. I see that per the verifiability policy, "If available, academic and peer-reviewed publications are usually the most reliable sources on topics such as history, medicine, and science." Given the size of the study, risk of bias, and the source (JAMA), it seems solid enough, but if reliable sources differ, that matters. I don't want to jump the gun, but I'm not convinced we need to wait. Also, the editorial IS a secondary source. LOL, you've made ~leetk (1337k) edits, Boghog. RememberOrwell (talk) 07:17, 26 June 2024 (UTC)[reply]
Seven (stavudine (86.4 eptkpy), erlotinib, lenalidomide ?"or"? thalidomide, chlorpromazine, metronidazole, prochlorperazine, isoniazid) had 10+ events per 10 000 person-years (eptkpy), while ten (moxifloxacin, azathioprine, levofloxacin, clarithromycin, ketoconazole, fluconazole, captopril, amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, ciprofloxacin) had 5-10 eptkpy. Eleven of these (64%) were not included in the highest hepatotoxicity category of LiverTox. RememberOrwell (talk) 05:23, 29 June 2024 (UTC)[reply]

There is a requested move discussion at Talk:Transgender hormone therapy#Requested move 15 July 2024 that may be of interest to members of this WikiProject. RodRabelo7 (talk) 16:08, 21 July 2024 (UTC)[reply]

Request for excerpt of text, from Archiv der Pharmazie (1987)

[edit]

In furtherance of editing an article, we would ask that any individual having access to a chemistry, pharmacology, or medical library that could give access to the following article,

  • Rücker G, Neugebauer M, Neugebauer M, Heiden PG (December 1987). "Zur chemischen Stabilität des Fenetyllins" [The chemical stability of fenethylline]. Archiv der Pharmazie (in German). 320 (12): 1272–1275. doi:10.1002/ardp.198700045. PMID 3439867. S2CID 84235752.

that they copy and paste the relevant synthetic text into a Talk entry at the Fenethylline article. That article presents a scheme in the Synthesis section, and the aim of consulting this source is to verify that the Scheme reflects the content of this source (per WP:VERIFY). Specifically, the scheme shows conversion of theophylline into a 7-(β-chloroethyl)-analog by treatment of the parent compound with a 1,2-dihaloethane, and then conversion of that analog, by treatment with the free base of amphetamine, to the fenethylline product (a codrug composed of theophylline and amphetamine linked by a two carbon bridge).

Our presumption is that in performing the chemical stability studies reported in the Archiv der Pharmazie abstract, Rücker et al first had to prepare the chemical sample they studied, hence this paper might contain a proscribed, quotable (copyable) synthetic method, and perhaps a scheme corresponding to the one at the Fenethylline article. Any of the relevant quoted German text, pasted at Talk for that article, and any further comment you would wish to make, would be greatly appreciated, and would likely allow us to verify the information attributed to this source. Thank you. 98.206.30.195 (talk) 03:01, 26 July 2024 (UTC)[reply]

See my comment at Talk:Aclarubicin. Opinions welcome. Thanks, MidnightBlue (Talk) 22:31, 27 July 2024 (UTC)[reply]